2021年世界肺癌大会（WCLC）将于9月8日至14日以全球虚拟网络会议的形式隆重召开，作为世界上最大的肺癌和其他胸部恶性肿瘤会议，WCLC吸引着全球专家学者的目光，最新前沿进展令人目接不暇。WCLC日程目前已经公布，“Mini Oral Session”共计17个，多位中国学者将在其中11个专场汇报最新研究成果。【肿瘤资讯】带您抢先一览！
“Mini Oral Session”的中国好声音
专场：MA01 - Multimodality Management of Advanced Lung Cancer（2021.9.8）
报告标题：MA01.05 - Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial
演讲者：Jianjiao Ni
专场：MA02 - RET and Novel Combinations of Osimertinib（2021.9.8）
报告标题：MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
演讲者：陆舜教授，上海市交通大学附属胸科医院
报告标题：MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer
演讲者：周清教授，广东省肺癌研究所，广东省人民医院
报告标题：MA02.06 - Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
演讲者：张力教授，中山大学肿瘤防治中心
专场：MA03 - Biomarkers for Immunotherapy: Are All Relevant?（2021.9.8）
报告标题：MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors
演讲者：Wei Nie
报告标题：MA03.07 - Interferon-Gamma Mediated Immune Evasion: A Potential Mechanism of Resistance to Immunotherapy in Non-Small Cell Lung Cancer
演讲者：Fasheng Li
专场：MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma（2021.9.8）
报告标题：MA04.02 - Characteristics of Genomic Alterations in Chinese Patients with Thymic Epithelial Tumors
演讲者：范兴龙，山东大学齐鲁医院
专场：MA07 - Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC（2021.9.9）
报告标题：MA07.07 - High Sensitivity of Detecting Stage I Lung Cancer Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell Free DNA
演讲者：郭伟，山西省肿瘤医院
专场：MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC（2021.9.9）
报告标题：MA08.05 - Integrating Genomic and Transcriptomic Features Predict the Recurrence Risk of Stage IA Non-Small Cell Lung Cancer
演讲者：Shirong Zhang
报告标题：MA08.07 - Immune Characteristics Associated With Lymph Node Metastasis in Early-Stage NSCLC Discovered via T Cell Receptor Repertoires Sequencing
演讲者：李敏教授，中南大学湘雅医院
专场：MA09 - Predictive Markers for Immunotherapy（2021.9.12）
报告标题：MA09.03 - Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
演讲者：Kan Wu
专场：MA11 - New Biological Insights for Targeted Therapies（2021.9.12）
报告标题：MA11.02 - Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
演讲者：Han Han
报告标题：Phase Separation of EML4-ALK in Firing Downstream Signaling and Promoting Lung Tumorigenesis
演讲者：Zhen Qin
报告标题：MA11.05 - Lysyl Oxidase Inhibition Drives Adenocarcinoma to Squamous Cell Carcinoma Transition and Promotes Drug Resistance
演讲者：YUEQING CHEN
报告标题：Lung Squamous Cell Carcinoma Prognosis Based on Ferroptosis DNA Methylation status
演讲者：Xuequan Wang
专场：MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?（2021.9.13）
报告标题：MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
演讲者：任胜祥教授，同济大学附属上海市肺科医院
报告标题：MA13.05 - Prognostic Impact of Immune Related Adverse Events in Advanced Non-Small Cell Lung Cancer Patients with ICIs Treatment
演讲者：王慧娟教授，河南省肿瘤医院
报告标题：MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
演讲者：周彩存教授，同济大学附属上海市肺科医院
报告标题：MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
演讲者：王洁教授，中国医学科学院肿瘤医院
专场：MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies（2021.9.13）
报告标题：MA16.05 - PI3K/Akt/mTOR Signaling Orchestrates the Phenotypic Transition and Chemo-Resistance of Small Cell Lung Cancer
演讲者：Xuefeng Li
专场：MA17 - Diagnostics and Pulmonology（2021.9.13）
报告标题：MA17.01 - Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
演讲者：Yi-Luen Shen
报告标题：MA17.04 - Leave Paraesophageal Lymph Node or Not in a Lung Cancer Surgery? A Propensity-Matched Analysis Based on Ten-Year Population.
演讲者：Xiaofei Wang
更多详情请至官网查看：https://library.iaslc.org/conference-program?product_id=24
本文根据官方日程仅统计“Mini Oral Session”中国专家报告内容，其他Session内容将陆续更新，如有遗漏或补充请联系肿瘤资讯-小编，微信号：oncologynews。
排版编辑：MJ
苏公网安备 32059002004080号
